Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma

Jaime O. Claudio, A. Keith Stewart

Research output: Contribution to journalReview article

3 Scopus citations


Pharmacogenomic studies in multiple myeloma, a neoplasia of clonally expanded malignant bone marrow plasma cells, are helping to set the stage for individualized therapy. Although relatively few in numbers, these studies are already providing new therapeutic targets and avenues for drug discoveries as well as contributing to novel prognostic markers in multiple myeloma. High-throughput mutation screening of the kinome promises to identify further novel targets for therapy. Genetics and gene expression profiling technology have improved molecular-based patient stratification and prognostic staging, expanded knowledge of the molecular mechanism of chemotherapeutic agents, and provided a better understanding of myeloma bone disease. The use of pharmacogenomic strategies in myeloma is thus already changing medical practice.

Original languageEnglish (US)
Pages (from-to)35-43
Number of pages9
JournalAmerican Journal of PharmacoGenomics
Issue number1
StatePublished - Jun 23 2005


ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this